Amgen vs BYD: Founders, CEOs and History
Amgen was founded in 1980 by George B. Rathmann, William K. Bowes Jr. and is led by Robert A. Bradway. BYD was founded in 1995 by Wang Chuanfu, Lu Xiangyang and is led by Wang Chuanfu.
Company facts
Founders
Amgen
George B. Rathmann
Amgen, originally incorporated as Applied Molecular Genetics, was founded in 1980 not by a single scientist, but by a calculated syndicate of venture capitalists and academics trying to commercialize the brand-new science of recombinant DNA.
William K. Bowes Jr.
William K. Bowes Jr. Was the venture capital strategist whose vision catalyzed Amgen's formation.
BYD
Wang Chuanfu
Wang Chuanfu founded BYD in Shenzhen in 1995 with his cousin Lu Xiangyang to make rechargeable batteries for mobile phones.
Lu Xiangyang
Lu Xiangyang put up the early capital when Wang Chuanfu started BYD in 1995 and has sat on BYD's board ever since, now as a non-executive director. His stake in BYD made him one of China's richest people.
CEOs and their tenures
Amgen
- George B. Rathmann1980–1988
Chief Executive Officer
George Rathmann, a physical chemist who had run research and development at Abbott Laboratories, was named Amgen's first chief executive in 1980 and worked from a small trailer so that laboratory space could go to scientists.
Source - Gordon M. Binder1988–2000
Chief Executive Officer
Gordon Binder joined Amgen as chief financial officer in 1982 and led its June 1983 initial public offering.
Source - Kevin W. Sharer2000–2012
Chief Executive Officer
Kevin Sharer joined Amgen in 1992 as president and chief operating officer and became chairman and chief executive in 2000.
Source - Robert A. Bradway2012–present
Chairman and Chief Executive Officer
Robert Bradway became chief executive on May 23, 2012, succeeding Kevin Sharer as the fourth CEO in Amgen's history, and added the chairmanship at the start of 2013.
Source
BYD
- Wang Chuanfu1995–present
Founder, Chairman and President (CEO)
Wang Chuanfu has run BYD since founding it in 1995. He moved the company from phone batteries into cars in 2003, launched the first mass-produced plug-in hybrid in 2008, introduced the Blade Battery in 2020 and ended combustion-only car production in 2022.
Source - Lu Xiangyang1995–present
Co-Founder and Non-Executive Director
Lu Xiangyang, Wang Chuanfu's cousin and a former banker, provided early capital for BYD in 1995 and has remained on the board, now as a non-executive director.
Source - Stella Li1996–present
Executive Vice President; CEO of BYD Americas and Europe
Stella Li joined BYD in September 1996 as a marketing manager for exports, opened its first overseas office in Hong Kong in 1997 and set up its European headquarters in 1999.
Source
Timeline: Amgen and BYD side by side
1980Amgen
Applied Molecular Genetics is incorporated
Applied Molecular Genetics (AMGen) was incorporated on April 8, 1980 in Thousand Oaks, California, as the idea of venture capitalist William K. Bowes Jr. and a group of scientific collaborators.
1983Amgen
Nasdaq listing and the erythropoietin clone
Amgen completed its initial public offering on June 17, 1983, raising nearly US$40 million under chief financial officer Gordon Binder, and formally shortened its name to Amgen.
1984Amgen
Kirin-Amgen joint venture formed
Amgen and Kirin Brewery Company of Japan formed Kirin-Amgen in 1984 as a joint venture for the worldwide commercialization of erythropoietin.
1985Amgen
G-CSF cloned, leading to Neupogen
While Fu-Kuen Lin's team worked on erythropoietin, researcher Larry Souza and his group cloned and expressed human granulocyte colony-stimulating factor in 1985.
1989Amgen
FDA approves Epogen
The FDA approved Epogen (epoetin alfa) on June 1, 1989 for anemia in patients with chronic kidney failure on dialysis. It was the first commercial recombinant human erythropoietin. Epogen's U.S.
1991Amgen
Neupogen approved, giving Amgen a second franchise
The FDA approved Neupogen (filgrastim) in February 1991. By stimulating white blood cell production it reduced the risk of infection in cancer patients with chemotherapy-induced neutropenia.
1991Amgen
Amgen wins the erythropoietin patent fight
On March 6, 1991 the U.S. Court of Appeals for the Federal Circuit upheld the Kirin-Amgen erythropoietin patent and ruled against Genetics Institute in Amgen v. Chugai Pharmaceutical and Genetics Institute.
1995BYD
BYD founded in Shenzhen
Wang Chuanfu and his cousin Lu Xiangyang start BYD in Shenzhen with about 20 employees, making rechargeable batteries for mobile phones.
2000BYD
Becomes a leading NiCd battery maker
BYD becomes one of the world's largest makers of nickel-cadmium batteries, supplying major electronics brands.
2001Amgen
FDA approves Aranesp, the longer-acting EPO
Aranesp (darbepoetin alfa), an erythropoietin analogue with modified glycosylation and a longer half-life, was approved in 2001. Less frequent dosing than Epogen improved convenience and gave Amgen a newer, higher-priced product to migrate patients toward.
2002Amgen
US$16 billion Immunex acquisition brings Enbrel in-house
Amgen completed its acquisition of Immunex Corporation on July 16, 2002, the largest biotechnology deal to that point at about US$16 billion in stock and cash.
2002BYD
Hong Kong listing
BYD lists its H shares on the Hong Kong Stock Exchange under stock code 1211.
2003BYD
Buys Qinchuan and enters the car business
BYD acquires a controlling stake in Xi'an Qinchuan Automobile for about $37.4 million (CN¥269 million), gaining a car production licence and factory.
2008BYD
Berkshire Hathaway takes about 10%
Berkshire Hathaway's MidAmerican Energy invests $232 million for about 10% of BYD, giving the company international credibility.
2008BYD
Launches the F3DM plug-in hybrid
BYD launches the F3DM, the world's first mass-produced plug-in hybrid car, two years before the Chevrolet Volt.
2010Amgen
Prolia and XGEVA create the bone health franchise
The FDA approved Prolia (denosumab) for postmenopausal osteoporosis in June 2010 and XGEVA, the same molecule at a higher dose, for prevention of skeletal-related events in cancer patients in November 2010.
2010BYD
Denza joint venture with Daimler
BYD and Daimler set up Denza as a 50:50 joint venture to build premium electric cars in China.
2011BYD
Launches the e6 and lists in Shenzhen
BYD launches the e6 electric crossover, first used as a taxi in Shenzhen, and lists A shares on the Shenzhen Stock Exchange (002594).
2019Amgen
US$13.4 billion purchase of Otezla from Celgene
Amgen agreed in August 2019 to buy worldwide rights to Otezla (apremilast) from Celgene for US$13.4 billion in cash, or about US$11.2 billion net of the present value of US$2.2 billion of anticipated future cash tax benefits, and closed on November 21, 2019.
2020Amgen
Amgen joins the Dow Jones Industrial Average
Amgen replaced Pfizer in the Dow Jones Industrial Average on August 31, 2020, becoming one of the thirty components in the index. Inclusion recognized the scale Amgen had reached and added passive demand from Dow-tracking funds.
2020BYD
Launches the Blade Battery
BYD introduces the Blade Battery, an LFP cell-to-pack design that passes the nail penetration test without fire.
2022BYD
Ends combustion-only car production
In March 2022 BYD stops making combustion-only passenger cars and focuses entirely on battery EVs and plug-in hybrids.
2023Amgen
US$27.8 billion Horizon Therapeutics acquisition closes
Amgen completed the acquisition of Horizon Therapeutics plc on October 6, 2023 for US$116.50 per share in cash, an equity value of about US$27.8 billion, after settling FTC litigation with a behavioral consent decree.
2023BYD
Passes Tesla in quarterly BEV sales
BYD sells 3.02 million new energy vehicles in 2023, and its 526,409 battery EVs in the fourth quarter top Tesla's 484,507 for the first time in a quarter.
2024Amgen
Imdelltra becomes the first T-cell engager for small cell lung cancer
The FDA granted accelerated approval to tarlatamab, sold as Imdelltra, on May 16, 2024 for extensive stage small cell lung cancer that has progressed on or after platinum-based chemotherapy.
2024BYD
Takes full ownership of Denza
Mercedes-Benz sells its last 10% of Denza in July 2024, leaving BYD as the sole shareholder of its premium brand.
2025Amgen
VESALIUS-CV extends the Repatha case to primary prevention
In November 2025 Amgen reported Phase 3 VESALIUS-CV results in more than 12,000 patients with atherosclerosis or diabetes but no prior heart attack or stroke.
2025BYD
Berkshire Hathaway exits
Berkshire Hathaway confirms in September 2025 that it has sold its entire BYD stake, ending a 17-year investment.
2025BYD
Becomes the world's top battery EV seller
BYD sells 2.26 million battery EVs in 2025 against Tesla's 1.64 million, and 4.6 million new energy vehicles in total.
2026Amgen
Medicare price setting reaches Enbrel and Otezla
Enbrel's negotiated Medicare price under the Inflation Reduction Act took effect on January 1, 2026, after it was named in the first round of ten drugs selected for negotiation.
2026BYD
Unveils Blade Battery 2.0 and FLASH charging
On March 5, 2026 BYD unveils the second-generation Blade Battery, which charges from 10% to 70% in about five minutes, and plans 20,000 FLASH charging stations in China by the end of 2026.
2026BYD
Overseas revenue passes China
In the first half of 2026 BYD's overseas revenue of ~$25.2 billion (CN¥181.3 billion) exceeds revenue from China for the first time, even as group revenue falls 7.1% to ~$47.9 billion (CN¥344.8 billion).
Acquisitions
Amgen
- Horizon Therapeutics plc2023$27.8B
- ChemoCentryx, Inc.2022$3.7B
- Five Prime Therapeutics2021$1.9B
- Celgene Otezla Business2019$13.4B
- Onyx Pharmaceuticals, Inc.2013$10.4B
- DeCODE Genetics2012$415M
BYD
- Denza (remaining stake from Mercedes-Benz)2024Undisclosed
- Jabil mobile electronics manufacturing business (China)2023$2B
- Xi'an Qinchuan Automobile2003$32M
Questions about Amgen vs BYD
Who is the CEO of Amgen Inc. and BYD Company Ltd?
Amgen Inc. is led by Robert A. Bradway and BYD Company Ltd is led by Wang Chuanfu. Both serve as the top executive responsible for the company's strategy, operations, and financial performance.
When was Amgen Inc. founded vs BYD Company Ltd?
Amgen Inc. was founded in 1980 — 15 years before BYD Company Ltd, which was founded in 1995. Amgen Inc.'s longer operating history gives it a deeper track record but also potentially more institutional inertia compared to the younger BYD Company Ltd.
How many employees does Amgen Inc. have compared to BYD Company Ltd?
Amgen Inc. employs approximately 31,500 people, while BYD Company Ltd employs approximately 911,900. BYD Company Ltd has the larger workforce at 911,900 employees, compared to Amgen Inc.'s 31,500. A higher headcount does not necessarily imply greater efficiency — it often reflects differences in business model (e.g., manufacturing vs. software).
Where are Amgen Inc. and BYD Company Ltd headquartered?
Amgen Inc. is headquartered in United States and BYD Company Ltd is headquartered in China. Their different home markets mean they may face different regulatory frameworks, tax regimes, and currency exposure.
Who founded Amgen Inc. and BYD Company Ltd?
Amgen Inc. was founded by George B. Rathmann, William K. Bowes Jr.. BYD Company Ltd was founded by Wang Chuanfu, Lu Xiangyang.
Which company has a longer operating history — Amgen Inc. or BYD Company Ltd?
Amgen Inc. has been operating for approximately 46 years, making it the more established of the two companies. BYD Company Ltd has been in operation for around 31 years. A longer operating history often signals greater institutional resilience and brand recognition, though it can also mean slower adaptation to new market conditions.
Figures come from each company's filings and the sources linked beside them. Amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Back to the Amgen vs BYD overview